Literature DB >> 15890425

Evaluation of anatomy-based dwell position and inverse optimization in high-dose-rate brachytherapy of prostate cancer: a dosimetric comparison to a conventional cylindrical dwell position, geometric optimization, and dose-point optimization.

Yasuo Yoshioka1, Tetsuo Nishimura, Minoru Kamata, Hideyuki Harada, Kenta Kanazawa, Hiroshi Fuji, Shigeyuki Murayama.   

Abstract

BACKGROUND AND
PURPOSE: To compare treatment planning methods in high-dose-rate (HDR) brachytherapy of prostate cancer. In particular, to assess quantitatively the dosimetric superiority, if any, of the anatomy-based dwell position (ABDP) and inverse optimization (IO) over the conventional cylindrical dwell position (CDP), geometric optimization (GO), and dose-point optimization (DO) in terms of the determination of dwell positions and dwell times. PATIENTS AND METHODS: Between September 2002 and April 2003, 10 cases of treatment-planning CT images were taken for external radiotherapy for prostate cancer. Treatment planning computer software and the CT data were used to create hypothetical HDR brachytherapy applicator needles, which were properly implanted in the prostate. Six different plans including IO with ABDP (IO(ABDP)), IO with CDP (IO(CDP)), GO with ABDP (GO(ABDP)), GO with CDP (GO(CDP)), DO with ABDP (DO(ABDP)), and DO with CDP (DO(CDP)) were made for each case, that is, 60 plans in total. All plans were normalized so that the D(95) should be equal to 100% of the prescribed dose. Dose-volume histograms from all 60 plans were analyzed, and multiple implant quality indices, including CI, EI, DNR, %V(R 75), %V(B 75), and %V(U 150) for each plan, were extracted and compared. Then, the best settings for IO(ABDP) regarding dwell position and dose limit were sought for.
RESULTS: ABDP showed a statistically significantly lower EI (P<0.001), %V(R 75) (P=0.002), and %V(B 75) (P=0.015) than CDP. IO showed a statistically significantly lower %V(U 150) than GO (P=0.009), or than DO (P<0.001). Given a definition that a figure exceeding three-fold of the minimum figure of the index is clinically unacceptable, only in IO(ABDP) all index figures were clinically acceptable, while in the other five plans at least one index figure was unacceptable.
CONCLUSIONS: In the CT-based treatment planning for prostate HDR brachytherapy, ABDP is useful to achieve a high conformity, which leads to a reduction of the doses to the bladder, rectum, and surrounding normal tissue. IO is useful to lower the urethral dose without sacrificing conformity. IO(ABDP) is recommended on the basis of the current study. However, this conclusion has been drawn from the idealized hypothetical settings, and some possibility remains that this conclusion is not always applicable to the real implants.

Entities:  

Mesh:

Year:  2005        PMID: 15890425     DOI: 10.1016/j.radonc.2005.02.006

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

1.  The effect of needle number on the quality of high-dose-rate prostate brachytherapy implants.

Authors:  Georgina Fröhlich; Péter Agoston; József Lövey; Csaba Polgár; Tibor Major
Journal:  Pathol Oncol Res       Date:  2010-03-25       Impact factor: 3.201

2.  Dosimetric evaluation of high-dose-rate interstitial brachytherapy boost treatments for localized prostate cancer.

Authors:  Georgina Fröhlich; Péter Agoston; József Lövey; András Somogyi; János Fodor; Csaba Polgár; Tibor Major
Journal:  Strahlenther Onkol       Date:  2010-06-24       Impact factor: 3.621

Review 3.  The evolution of brachytherapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz
Journal:  Nat Rev Urol       Date:  2017-06-30       Impact factor: 14.432

Review 4.  Current status and perspectives of brachytherapy for prostate cancer.

Authors:  Yasuo Yoshioka
Journal:  Int J Clin Oncol       Date:  2009-02-20       Impact factor: 3.402

5.  Class solution in inverse planned HDR prostate brachytherapy for dose escalation of DIL defined by combined MRI/MRSI.

Authors:  Yongbok Kim; I-Chow J Hsu; Etienne Lessard; John Kurhanewicz; Susan Moyher Noworolski; Jean Pouliot
Journal:  Radiother Oncol       Date:  2008-02-20       Impact factor: 6.280

6.  An audit of high dose-rate prostate brachytherapy treatment planning at six Swedish clinics.

Authors:  Frida Dohlmar; Sakarias Johansson; Torbjörn Larsson; Michael Sandborg; Åsa Carlsson Tedgren
Journal:  J Contemp Brachytherapy       Date:  2021-02-18

Review 7.  High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective.

Authors:  Yasuo Yoshioka; Osamu Suzuki; Yuki Otani; Ken Yoshida; Takayuki Nose; Kazuhiko Ogawa
Journal:  J Contemp Brachytherapy       Date:  2014-04-03

8.  Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.

Authors:  Shoichi Fukuda; Yuji Seo; Hiroya Shiomi; Yuji Yamada; Toshiyuki Ogata; Masahiro Morimoto; Koji Konishi; Yasuo Yoshioka; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2014-06-23       Impact factor: 2.724

9.  Dosimetric Evaluation of Different Optimization Algorithms Used in Interstitial Brachytherapy of Cervical Carcinoma.

Authors:  Shraddha Srivastava; Navin Singh; Varun Kumar Kashyap
Journal:  J Biomed Phys Eng       Date:  2022-08-01

10.  Inverse planning for combination of intracavitary and interstitial brachytherapy for locally advanced cervical cancer.

Authors:  Kotaro Yoshio; Naoya Murakami; Madoka Morota; Ken Harada; Mayuka Kitaguchi; Kentaro Yamagishi; Shuhei Sekii; Kana Takahashi; Koji Inaba; Hiroshi Mayahara; Yoshinori Ito; Minako Sumi; Susumu Kanazawa; Jun Itami
Journal:  J Radiat Res       Date:  2013-05-31       Impact factor: 2.724

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.